Back to News
Market Impact: 0.38
AC Immune Posts Positive Week 100 Phase 2 Data For ACI-7104 In Parkinson's Disease; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
AC Immune reported positive Week-100 results from Part 1 of its Phase 2 VacSYn trial of ACI-7104 in patients with early-stage Parkinson's disease. The long-duration positive clinical update supports continued development of the vaccine candidate and is a favorable catalyst for AC Immune shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
ACIU0.82
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- Good riddance, Cybertruck!
- Airbnb: 3 Key Takeaways for Long-Term Investors
- Claude Personal Finance vs. ChatGPT Finances: What sets them apart?